VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women
- PMID: 15836797
- PMCID: PMC1087887
- DOI: 10.1186/1477-9560-3-5
VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women
Abstract
BACKGROUND: Community-based cohort studies are not available that evaluated the predictive power of both clinical and genetic risk factors for venous thromboembolism (VTE). There is, however, clinical need to forecast the likelihood of future occurrence of VTE, at least qualitatively, to support decisions about intensity of diagnostic or preventive measures. MATERIALS AND METHODS: A 10-year observation period of the Bavarian Thromboembolic Risk (BATER) study, a cohort study of 4337 women (18-55 years), was used to develop a predictive model of VTE based on clinical and genetic variables at baseline (1993). The objective was to prepare a probabilistic scheme that discriminates women with virtually no VTE risk from those at higher levels of absolute VTE risk in the foreseeable future. A multivariate analysis determined which variables at baseline were the best predictors of a future VTE event, provided a ranking according to the predictive power, and permitted to design a simple graphic scheme to assess the individual VTE risk using five predictor variables. RESULTS: Thirty-four new confirmed VTEs occurred during the observation period of over 32,000 women-years (WYs). A model was developed mainly based on clinical information (personal history of previous VTE and family history of VTE, age, BMI) and one composite genetic risk markers (combining Factor V Leiden and Prothrombin G20210A Mutation). Four levels of increasing VTE risk were arbitrarily defined to map the prevalence in the study population: No/low risk of VTE (61.3%), moderate risk (21.1%), high risk (6.0%), very high risk of future VTE (0.9%). In 10.6% of the population the risk assessment was not possible due to lacking VTE cases. The average incidence rates for VTE in these four levels were: 4.1, 12.3, 47.2, and 170.5 per 104 WYs for no, moderate, high, and very high risk, respectively. CONCLUSION: Our prognostic tool - containing clinical information (and if available also genetic data) - seems to be worthwhile testing in medical practice in order to confirm or refute the positive findings of this study. Our cohort study will be continued to include more VTE cases and to increase predictive value of the model.
Figures

Similar articles
-
Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study.Thromb J. 2005 Jul 20;3:8. doi: 10.1186/1477-9560-3-8. Thromb J. 2005. PMID: 16029515 Free PMC article.
-
[The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].Dtsch Med Wochenschr. 2000 Jan 7;125(1-2):2-6. doi: 10.1055/s-2007-1023875. Dtsch Med Wochenschr. 2000. PMID: 10650817 German.
-
Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.PLoS Med. 2015 Nov 10;12(11):e1001899; discussion e1001899. doi: 10.1371/journal.pmed.1001899. eCollection 2015 Nov. PLoS Med. 2015. PMID: 26554832 Free PMC article.
-
Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk.Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:106-11. doi: 10.1016/j.ejogrb.2015.06.005. Epub 2015 Jun 16. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 26115054 Review.
-
Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease.Semin Hematol. 2001 Apr;38(2 Suppl 5):12-9. doi: 10.1016/s0037-1963(01)90094-0. Semin Hematol. 2001. PMID: 11449339 Review.
Cited by
-
Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23. Blood. 2008. PMID: 18216292 Free PMC article.
-
Using pathology-specific laboratory profiles in clinical pathology to reduce inappropriate test requesting: two completed audit cycles.BMC Health Serv Res. 2012 Jul 3;12:187. doi: 10.1186/1472-6963-12-187. BMC Health Serv Res. 2012. PMID: 22759353 Free PMC article.
-
Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study.BMJ. 2011 Aug 16;343:d4656. doi: 10.1136/bmj.d4656. BMJ. 2011. PMID: 21846713 Free PMC article.
-
Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study.Thromb J. 2005 Jul 20;3:8. doi: 10.1186/1477-9560-3-8. Thromb J. 2005. PMID: 16029515 Free PMC article.
References
-
- Backer GD, Ambrosioni E, Borch-Johnsen K, Broton C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman o, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular prevention in clinical practice. Third task force of Europeean and other societies on cardiovascular disease prevenetion in clinical practice. Eur J Cardiovasc Prevent Rehab. 2003;10:S1–S10. - PubMed
-
- Empana JP, Dulcimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amouyel P, Dallongeville J, on behalf of the PRIME Study Group Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME study. Eur Heart J. 2003;24:1903–11. doi: 10.1016/j.ehj.2003.09.002. - DOI - PubMed
-
- Schramm W, Heinemann LAJ, Spannagl M, Dick A, Assmann A. Die BAyerischen Thrombo-Embolie-Risiko Kohortenstudie (BATER). Studienprotokoll, Stand der Untersuchung und erste Ergebnisse. Dtsch Med Wschr. 2000;125:2–6. - PubMed
-
- Spannagl M, Dick A, Assmann A, Heinemann L, Schramm W. Resistance to activated protein C in women using oral contraceptives. Sem Thrombosis Hemostasis. 1998;24:423–430. - PubMed
LinkOut - more resources
Full Text Sources